Positron-Emission Tomography Clinical Trial
Official title:
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with selected advanced and metastatic solid malignancies who are scheduled to receive standard of care immunotherapy. The study will also evaluate uptake of ⁸⁹Zr-Df-IAB22M2C by PET/CT in patients at baseline and on immunotherapy.
After being informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Up to 1 week prior to initiation of immunotherapy, patients will receive an injection of ⁸⁹Zr-Df-IAB22M2C (1.0 mCi) and will undergo PET/CT scanning to determine baseline uptake of ⁸⁹Zr-Df-IAB22M2C in tumor lesions and reference tissues. Patients will receive an additional injection of ⁸⁹Zr-Df-IAB22M2C (1.0 mCi) and PET/CT scan 4-6 weeks after starting immunotherapy (on-therapy) to evaluate uptake of ⁸⁹Zr-Df-IAB22M2C in tumor lesions and reference tissues, and to assess potential changes in uptake of ⁸⁹Zr-Df-IAB22M2C compared to the baseline scan. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04555642 -
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
|
||
Recruiting |
NCT05004961 -
The Performance of Multi-tracer Multimodality PET in Lymphoma
|
||
Recruiting |
NCT05188872 -
Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE
|
N/A | |
Recruiting |
NCT04983095 -
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05610098 -
Gene Expression Profiles in Spinal Tuberculosis.
|
||
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
Recruiting |
NCT04831541 -
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
|
Early Phase 1 | |
Recruiting |
NCT06188468 -
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors
|
N/A | |
Recruiting |
NCT06017973 -
The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
|
N/A | |
Recruiting |
NCT03830242 -
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
|
N/A | |
Recruiting |
NCT06387381 -
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
|
Early Phase 1 | |
Recruiting |
NCT05506566 -
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04367948 -
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
|
N/A | |
Recruiting |
NCT05757804 -
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
|
||
Completed |
NCT05392205 -
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
|
N/A | |
Completed |
NCT03741231 -
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
|
||
Completed |
NCT01035164 -
Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03107663 -
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
|
Phase 1 | |
Recruiting |
NCT03636607 -
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
|
N/A |